(4-cyclohexylphenyl)methyl pyridin-2-yl carbonate | 1439367-97-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-cyclohexylphenyl)methyl pyridin-2-yl carbonate
• 英文别名: (4-cyclohexylphenyl)-methyl 2-pyridyl carbonate；(4-cyclohexylphenyl)methyl 2-pyridyl carbonate；(4-cyclohexylphenyl)methyl 2-pyridylcarbonate
• CAS: 1439367-97-1
• 化学式: C₁₉H₂₁NO₃
• 分子量: 311.381
• InChiKey: CNNMFVDOWXQWMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.84
• 重原子数：
  23.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  48.42
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  对环己基苯甲酸 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 (4-cyclohexylphenyl)methyl pyridin-2-yl carbonate
  参考文献：
  名称：

  [EN] CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  [FR] DÉRIVÉS DE CARBAMATE D'INHIBITEURS D'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA) À BASE DE LACTAME

  摘要：

  公开号：

  WO2014144836A3

文献信息

• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。
• Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)
  申请人：The Regents of the University of California

  公开号：US09353075B2

  公开（公告）日：2016-05-31

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰基乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的紊乱的方法。
• Potent α-amino-β-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure–activity relationship (SAR) studies
  作者：Andrea Nuzzi、Annalisa Fiasella、Jose Antonio Ortega、Chiara Pagliuca、Stefano Ponzano、Daniela Pizzirani、Sine Mandrup Bertozzi、Giuliana Ottonello、Glauco Tarozzo、Angelo Reggiani、Tiziano Bandiera、Fabio Bertozzi、Daniele Piomelli

  DOI：10.1016/j.ejmech.2016.01.046

  日期：2016.3

  2-oxo-3-azetidinyl ring as well as on the effect of size and shape of the carbamic acid ester side chain led to the discovery of 3ak, a novel inhibitor of human NAAA that shows an improved physicochemical and drug-like profile relative to 3b. This favourable profile, along with the structural diversity of the carbamic acid chain of 3b, identify this compound as a promising new tool to investigate the potential

  4-环己基丁基-N -[（S）-2-氧杂氮杂环丁-3-基]氨基甲酸酯（3b）是一种有效的，选择性的和系统性的细胞内NAAA活性抑制剂，可在动物模型中产生深远的抗炎作用。在当前的工作中，我们描述了对3-氨基氮杂环丁烷-2-one衍生物的结构-活性关系（SAR）研究，该研究导致了3b的鉴定，并扩展了这些研究以阐明获得有效的结构和立体化学特征。 NAAA抑制。关于2-氧代-3-氮杂环丁烷基环的β-位取代的影响以及氨基甲酸酯侧链的大小和形状的影响的研究导致了3ak的发现。，一种人类NAAA的新型抑制剂，相对于3b而言，它具有改善的理化和类药物特性。这种有利的特性以及3b氨基甲酸酯链的结构多样性，使该化合物成为研究NAAA抑制剂作为治疗疼痛和炎症的潜力的有前途的新工具。
• Synthesis, Biological Evaluation, and 3D QSAR Study of 2-Methyl-4-oxo-3-oxetanylcarbamic Acid Esters as <i>N</i>-Acylethanolamine Acid Amidase (NAAA) Inhibitors
  作者：Stefano Ponzano、Anna Berteotti、Rita Petracca、Romina Vitale、Luisa Mengatto、Tiziano Bandiera、Andrea Cavalli、Daniele Piomelli、Fabio Bertozzi、Giovanni Bottegoni

  DOI：10.1021/jm501455s

  日期：2014.12.11

  N-(2-Oxo-3-oxetanyl)carbamic acid esters have recently been reported to be noncompetitive inhibitors of the N-acylethanolamine acid amidase (NAAA) potentially useful for the treatment of pain and inflammation. In the present study, we further explored the structure-activity relationships of the carbamic acid ester side chain of 2-methyl-4-oxo-3-oxetanylcarbamic acid ester derivatives. Additional favorable features in the design of potent NAAA inhibitors have been found together with the identification of a single digit nanomolar inhibitor. In addition, we devised a 3D QSAR using the atomic property field method. The model turned out to be able to account for the structural variability and was prospectively validated by designing, synthesizing, and testing novel inhibitors. The fairly good agreement between predictions and experimental potency values points to this 3D QSAR model as the first example of quantitative structure-activity relationships in the field of NAAA inhibitors.